The diagnosis and treatment of multiple myeloma has changed dramatically in the past
decade. The disease definition has been updated to include highly specific biomarkers in …

Big Data bring new opportunities to modern society and challenges to data scientists. On the
one hand, Big Data hold great promises for discovering subtle population patterns and …

Cell-based therapies are emerging as effective agents against cancer and other diseases.
As autonomous “living drugs,” these therapies lack precise control. Chimeric antigen …

Background Data are lacking on whether lenalidomide maintenance therapy prolongs the
time to disease progression after autologous hematopoietic stem-cell transplantation in …

Allogeneic natural killer (NK) cell adoptive transfer is a promising treatment for several
cancers but is less effective for the treatment of multiple myeloma. In this study, we report on …

Purpose Lenalidomide has significant single-agent activity in relapsed diffuse large B-cell
lymphoma (DLBCL). We demonstrated that lenalidomide can be safely combined with R …

Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell
malignancy, have dramatically improved. The development of the immunomodulatory drugs …

In most countries, healthcare service budgets are not likely to support the current explosion
in the cost of new oncology drugs. Repurposing the large arsenal of approved, non …

For decades, anticancer targeted therapies have been designed to inhibit kinases or other
enzyme classes and have profoundly benefited many patients. However, novel approaches …

Background Lenalidomide is a structural analogue of thalidomide with similar but more
potent biologic activity. This phase 3, placebo-controlled trial investigated the efficacy of …